Luvox Cr is a drug owned by Jazz Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 10, 2020. Details of Luvox Cr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7465462 | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
May, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Luvox Cr's patents.
Latest Legal Activities on Luvox Cr's Patents
Given below is the list of recent legal activities going on the following patents of Luvox Cr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 18 Jan, 2021 | US7465462 |
| Maintenance Fee Reminder Mailed Critical | 03 Aug, 2020 | US7465462 |
| Recordation of Patent Grant Mailed Critical | 16 Dec, 2008 | US7465462 |
| Patent Issue Date Used in PTA Calculation Critical | 16 Dec, 2008 | US7465462 |
| Issue Notification Mailed Critical | 25 Nov, 2008 | US7465462 |
| Dispatch to FDC | 18 Nov, 2008 | US7465462 |
| Mail Examiner's Amendment | 13 Nov, 2008 | US7465462 |
| Printer Rush- No mailing | 13 Nov, 2008 | US7465462 |
| Interview Summary Record | 06 Nov, 2008 | US7465462 |
| Pubs Case Remand to TC Critical | 29 Oct, 2008 | US7465462 |
US patents provide insights into the exclusivity only within the United States, but Luvox Cr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Luvox Cr's family patents as well as insights into ongoing legal events on those patents.
Luvox Cr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Luvox Cr's generic launch date based on the expiry of its last outstanding patent is estimated to be May 10, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Luvox Cr Generic API suppliers:
Fluvoxamine Maleate is the generic name for the brand Luvox Cr. 15 different companies have already filed for the generic of Luvox Cr, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Luvox Cr's generic
How can I launch a generic of Luvox Cr before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Luvox Cr's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Luvox Cr's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Luvox Cr -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 100 mg | 20 Apr, 2009 | 1 | 13 Mar, 2013 | 10 May, 2020 | Extinguished |
| 150 mg | 13 Apr, 2009 | 1 | 13 Mar, 2013 | 10 May, 2020 | Non-Forfeiture |
About Luvox Cr
Luvox Cr is a drug owned by Jazz Pharmaceuticals Inc. It is used for treating obsessive-compulsive disorder with an SSRI. Luvox Cr uses Fluvoxamine Maleate as an active ingredient. Luvox Cr was launched by Jazz Pharms in 2008.
Approval Date:
Luvox Cr was approved by FDA for market use on 28 February, 2008.
Active Ingredient:
Luvox Cr uses Fluvoxamine Maleate as the active ingredient. Check out other Drugs and Companies using Fluvoxamine Maleate ingredient
Treatment:
Luvox Cr is used for treating obsessive-compulsive disorder with an SSRI.
Dosage:
Luvox Cr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |
| 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | CAPSULE, EXTENDED RELEASE | Discontinued | ORAL |